These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23609023)

  • 21. Rapid quantification of urinary oxycodone and oxymorphone using fast gas chromatography-mass spectrometry.
    McKinley S; Snyder JJ; Welsh E; Kazarian CM; Jamerson MH; Klette KL
    J Anal Toxicol; 2007 Oct; 31(8):434-41. PubMed ID: 17988456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(2):175-87. PubMed ID: 21412372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.
    Kirvela M; Lindgren L; Seppala T; Olkkola KT
    J Clin Anesth; 1996 Feb; 8(1):13-8. PubMed ID: 8695073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.
    Edwards SR; Smith MT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 848(2):264-70. PubMed ID: 17098487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A transit compartment model unmasks OxyContin's reflective pharmacokinetics from urine measurements in humans.
    Linares OA; Schiesser WE; Linares AD; Stefanovski D; Boston RC
    J Pain Palliat Care Pharmacother; 2014 Jun; 28(2):96-108. PubMed ID: 24813654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Excretion profile of hydrocodone, hydromorphone and norhydrocodone in urine following single dose administration of hydrocodone to healthy volunteers.
    Valtier S; Bebarta VS
    J Anal Toxicol; 2012 Sep; 36(7):507-14. PubMed ID: 22782534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.
    Pöyhiä R; Seppälä T; Olkkola KT; Kalso E
    Br J Clin Pharmacol; 1992 Jun; 33(6):617-21. PubMed ID: 1389934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration.
    Klimas R; Witticke D; El Fallah S; Mikus G
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):517-28. PubMed ID: 23488585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions?
    Mikus G
    J Anal Toxicol; 2015; 39(1):81-2. PubMed ID: 25288721
    [No Abstract]   [Full Text] [Related]  

  • 30. Response to urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions.
    Elder NM; Atayee RS; Best BM; Ma JD
    J Anal Toxicol; 2015; 39(1):80. PubMed ID: 25288719
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of the DRI oxycodone immunoassay for the detection of oxycodone in urine.
    Backer RC; Monforte JR; Poklis A
    J Anal Toxicol; 2005 Oct; 29(7):675-7. PubMed ID: 16419399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tentative identification of novel oxycodone metabolites in human urine.
    Moore KA; Ramcharitar V; Levine B; Fowler D
    J Anal Toxicol; 2003 Sep; 27(6):346-52. PubMed ID: 14516487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Grapefruit juice enhances the exposure to oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):782-8. PubMed ID: 20406214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interpretation of oxycodone concentrations in oral fluid.
    Moore C; Kelley-Baker T; Lacey J
    J Opioid Manag; 2012; 8(3):161-6. PubMed ID: 22798176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
    Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
    Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.
    Huang L; Edwards SR; Smith MT
    Pharm Res; 2005 Sep; 22(9):1489-98. PubMed ID: 16132361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.
    Leuppi-Taegtmeyer A; Duthaler U; Hammann F; Schmid Y; Dickenmann M; Amico P; Jehle AW; Kalbermatter S; Lenherr C; Meyer Zu Schwabedissen HE; Haschke M; Liechti ME; Krähenbühl S
    Nephrol Dial Transplant; 2019 Apr; 34(4):692-702. PubMed ID: 30189012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Illicit drug use correlates with negative urine drug test results for prescribed hydrocodone, oxycodone, and morphine.
    Pesce A; West C; Gonzales E; Rosenthal M; West R; Mikel C; Almazan P; Latyshev S; Horn P
    Pain Physician; 2012; 15(5):E687-92. PubMed ID: 22996862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laboratory monitoring of OxyContin (oxycodone): clinical pitfalls.
    Von Seggern RL; Fitzgerald CP; Adelman LC; Adelman JU
    Headache; 2004 Jan; 44(1):44-7. PubMed ID: 14979882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Retrospective Analysis of Selected Opioids in Hair of Workplace Drug Testing Subjects.
    Stowe GN; Paulsen RB; Hill VA; Schaffer MI
    J Anal Toxicol; 2019 Aug; 43(7):553-563. PubMed ID: 31009051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.